Is Fam-trastuzumab deruxtecan-nxki on the market?

Fam-trastuzumabFam-trastuzumab deruxtecan-nxki) was approved for medical use in the United States in December 2019, in Japan in March 2020, in the European Union in January 2021, in Australia in October 2021, and in China in July 2023. Trastuzumab is the first treatment approved by the U.S. Food and Drug Administration (FDA) for patients with the HER2-low breast cancer subtype of HER2-negative cancer. Trastuzumab is sold under the brand name Enhertu.

Detrastuzumab is an antibody-drug conjugate consisting of the humanized monoclonal antibody (Trastuzumab) covalently linked to the topoisomerase I inhibitor deruxtekan (a derivative of exatecan). It is licensed to treat breast cancer, non-small cell lung cancer, or adenocarcinoma of the stomach or gastroesophagus. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) in cancers that rely on it for growth. In addition, once bound to the HER2 receptor, the antibody will be internalized by the cell, carrying the bound DNA, interfering with the cell's ability to make DNA structural changes and copy DNA during cell division, causing DNA damage when the cell attempts to copy itself, destroying the cell.

Trastuzumab is a new type of injectable anti-cancer drug. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is a strictly controlled drug and its purchase is restricted. The price of Trastuzumab original drug specifications100mg per box sold in Hong Kong may be more than RMB 10,000 (the price may fluctuate due to the exchange rate). There are currently no generics of Trastuzumab on the market. For more specific prices and drug information, please consult a medical consultant.